This content is from: Premium
There’s New Hope for the IPO Market
At least five hedge funds have benefited from two biopharma stocks that went public in February and are currently doing well.
A pair of IPOs this month is generating some cautious optimism that the new-issues market may have finally emerged from its bear market slumber. Both Mineralys Therapeutics and Structure Therapeutics are currently trading above their offering prices, with the latter up 62 percent. This
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.